Focused Update on Dual Antiplatelet Therapy (DAPT)

Publication Date: 2017

Chairperson: Marco Valgimigli & Héctor Bueno

Topics:

Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting stents, Myocardial infarction, Stent thrombosis, Bleeding, Percutaneous coronary intervention, Recommendation, Revascularization, Risk stratification, Stents, Stable angina, Stable coronary artery disease, Oral anticoagulant, Triple therapy, DAPT score, PRECISE-DAPT score, Non-cardiac surgery

2017-08-24

Pocket Guidelines on the 2017 Focused Update on Dual Antiplatelet Therapy

Link

2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)

Link

The estimated number of patients requiring dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and an oral inhibitor of the platelet P2Y₁₂ receptor for adenosine 5′-diphosphate (ADP), is considerable and has increased over time in Europe. Based on population estimates from 2015, in the region of 1 400 000 and 2 200 000 patients per year may have an indication for DAPT after coronary intervention or myocardial infarction (MI), respectively.